Axsome Therapeutics (AXSM) Capital Expenditures (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.42% |
| Dec 31, 2025 | 22.41% |
| Sep 30, 2025 | 346.15% |
| Jun 30, 2025 | -96.15% |
| Mar 31, 2025 | 1,026.67% |
| Dec 31, 2024 | -66.67% |
| Sep 30, 2024 | 73.08% |
| Jun 30, 2024 | -46.94% |
| Mar 31, 2024 | 1,300.00% |
| Dec 31, 2023 | -98.11% |
| Sep 30, 2023 | 178.95% |
| Jun 30, 2023 | 87.32% |
| Mar 31, 2023 | -60.77% |
| Dec 31, 2022 | 174.24% |
| Sep 30, 2022 | -72.61% |
| Jun 30, 2022 | 12.62% |
| Mar 31, 2022 | 47,350.11% |
| Dec 31, 2021 | -99.83% |
| Sep 30, 2021 | 1,270.33% |
| Jun 30, 2021 | -37.07% |
| Mar 31, 2021 | 47.85% |
| Dec 31, 2020 | 36.66% |
| Sep 30, 2020 | 939.57% |
| Jun 30, 2020 | -84.70% |
| Mar 31, 2020 | 538.67% |
| Dec 31, 2019 | -54.29% |
| Sep 30, 2018 | -12.01% |
| Jun 30, 2018 | -33.87% |
| Mar 31, 2018 | 1,457,500.00% |
| Dec 31, 2017 | -99.97% |
| Sep 30, 2017 | 6.13% |
| Jun 30, 2017 | 17.11% |
| Mar 31, 2017 | -52.12% |
| Dec 31, 2016 | -92.06% |
| Sep 30, 2016 | 557.31% |
| Jun 30, 2016 | 8.92% |
| Mar 31, 2016 | 159.02% |
| Dec 31, 2015 | -6.69% |
| Sep 30, 2015 | 210.35% |
| Jun 30, 2015 | -86.15% |